Pyoderma gangrenosum
MONDO:0018824Pyoderma gangrenosum (PG) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with a mucopurulent or hemorrhagic exudate.
20 clinical trials for this condition and its sub-types, 10 tagged with Pyoderma gangrenosum itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pyoderma gangrenosum
-
Classic pyoderma gangrenosum 3 trials
-
Bullous pyoderma gangrenosum 0 trials
-
Pustular pyoderma gangrenosum 0 trials
-
Vegetative pyoderma gangrenosum 0 trials
-
New injection aims to heal skin ulcers in rare disease
Disease control Recruiting nowThis phase 2 trial tests an injection called SHR-1139 in 10 adults with ulcerative pyoderma gangrenosum, a rare skin condition that causes painful, open sores. The main goal is to see if the drug can completely close the target ulcer within 12 weeks. Researchers will also check f…
Phase 2 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Phase 3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a psoriasis drug heal these stubborn skin ulcers?
Disease control Recruiting nowThis study tests guselkumab (Tremfya), a drug already used for psoriasis, in 17 adults with pyoderma gangrenosum—a rare disease that leads to painful, hard-to-heal skin ulcers. Participants receive injections every 4 weeks for 28 weeks. Researchers will check if ulcers heal compl…
Phase 2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC